Results filed 5 November 2026 · Market cap ₹27,764 crore · PE 85.5
GrowthGuidance raisedTranscript read
Revenue
+39.9%
on a year ago
EBITDA
+52.8%
on a year ago
Profit to shareholders
+68.0%
on a year ago
EBITDA margin
25.0%
+0.8 pts on last quarter
Rubicon Research reported Q2 FY27 revenue of ₹576 cr (up 39.9% YoY) and operating EBITDA of ₹144 cr (25.0% margin), leading management to increase full-year operating EBITDA margin guidance to 24%+. The company faces an operational drag from ₹396 cr of capital employed (>25% of total) in pre-revenue sites and Arinna whose pre-operative expenses flow through the P&L. Regulatory inspections were completed across all manufacturing sites in the past six months, leaving Ambernath, Satara, and Pithampur awaiting EIR closures following procedural Form 483 observations.
Rubicon Research Limited, Q2 FY27₹ crore, consolidated
Q2 FY27
Q1 FY27
vs previous quarter
Q2 FY26
vs a year ago
Revenue
576
534
+7.9%
412
+39.9%
Operating profit (EBIT)
126
114
+10.6%
82.43
+52.9%
Operating margin
21.9%
21.3%
+54 bps
20.0%
+186 bps
Other income
2.29
5.68
−59.7%
0.7
+227.1%
Exceptional items
0
0
–
0
–
Profit before exceptional items and tax
117
110
+5.9%
71.7
+63.1%
Profit to shareholders
90.48
84.78
+6.7%
53.85
+68.0%
Earnings per share (₹)
5.47
5.13
+6.6%
3.49
+56.7%
Source: Rubicon Research Limited’s filing to NSE, 5 November 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.
What stood out
Operating EBITDA margin expanded to 25.0% and management raised full-year FY27 operating EBITDA guidance to 24%+SourceNitin Jajodia and Parag Sancheti noted operating EBITDA reached INR 144 cr (25.0% margin) and raised guidance to '24% plus for the full year' (Transcript, original page 5; Presentation, original page 11)
Significant drag from pre-revenue assets, accounting for over 25% of capital employed with zero revenue and pre-op costs hitting P&LSourceTotal of INR 396.2 cr (Pithampur INR 158.1 cr, CSN INR 34.9 cr, New Jersey INR 29.1 cr, Arinna INR 174.1 cr) out of capital employed is pre-revenue or yet to materially contribute (Presentation, original page 8; Transcript, original page 4)
Four manufacturing sites and two R&D sites inspected by US FDA within six months; Ambernath received five observations and Satara received oneSourceSagar Oak confirmed unannounced inspections in Oct-26 led to 5 procedural observations at Ambernath and 1 at Satara with EIRs awaited (Transcript, original page 6; Presentation, original page 12)
Guidance
Metric
Guidance
Period
Operating EBITDA MarginSource'we had upped our Operating EBITDA Margin guidance for FY27 to 23%+ from 22-23%, and we now further up this guidance to 24%+ for FY27' (Presentation, original page 11)
24%+
FY27
Cumulative R&D SpendSource'On track to achieve guidance of INR 5,000 Mn+ R&D spend over 9 quarters i.e. FY26 + FY27 + Q1FY28 (INR 3,139 Mn spent in 6 quarters)' (Presentation, original page 14)
Net Working Capital DaysSource'NWCap would normalize in the typical 125-130 days over coming quarters' versus 117 days in H1 FY27 (Presentation, original page 8)
125-130 days
Coming quarters
Pithampur Facility CommercializationSourceParag Sancheti: 'For Indore, we have already said that it will be FY 2028 onwards for that' (Transcript, original page 11)
Revenue generation from FY28 onwards
FY28 onwards
Operating EBITDA margin guidance raised from 23%+ in Q1 FY27 to 24%+ in Q2 FY27
Tailwinds
Expanding contribution from high-margin specialty portfolioSourceSpecialty products contributed 36% of gross profit in H1 FY27, up from 32% in FY26 and 13% in FY23 (Presentation, original page 27)
Strong sequential and YoY revenue growth driven by portfolio breadthSourceRevenue from operations reached INR 576.4 cr, up 39.9% YoY and 7.9% QoQ (USD revenue up >5% QoQ to $58 mn) with balanced top-5 and top-10 concentration (Presentation, original pages 7, 11)
High product commercialization executionSourceCommercialization rate remained high at 84% (76 out of 90 active approved products commercialized) (Presentation, original page 30)
Headwinds
Pre-operating drag from newly acquired/under-construction facilitiesSourceOver 25% of capital employed (~INR 400 cr) across Pithampur, CSN, New Jersey, and Arinna is pre-revenue while operating expenses pass directly through P&L (Transcript, original pages 4, 10; Presentation, original page 8)
Regulatory export licensing change in India causing product launch delaysSourceParag Sancheti noted Indian rules changed so that export licenses can only be applied for after receiving FDA approval, delaying immediate post-approval shipments into next quarters (Transcript, original page 5)
Regulatory inspection overhang across manufacturing facilitiesSourceAmbernath received 5 procedural 483 observations in Oct-26 and Satara received 1 procedural observation in Oct-26, with EIRs awaited (Presentation, original page 12)
New businesses and products
acquisition · Acquired in July 2026; currently non-operational/pre-revenue awaiting filings and US FDA inspection
InvaTech New Jersey Manufacturing Facility Acquisition
Expected benefit
US-based manufacturing footprint for oral solids and oral liquids adjacent to AimRx 3PL distribution facility
Risks
Timeline uncertainty; requires product filings, tech transfers, and US FDA inspection prior to revenue generation
Timeline
Management refrained from giving an exact timeline
Investment
INR 84.7 cr addition to fixed assets (INR 29.1 cr cash outflow and INR 55.7 cr non-cash right-of-use lease liability)
SourceParag Sancheti: 'For New Jersey... it will take us, before we revenue starts, we will have to do filing, putting the products, and FDA inspection. Right now, we will refrain from giving an exact date' (Transcript, original page 11; Presentation, original pages 8, 34)
acquisition · Acquired in April 2026; consolidated in H1 FY27 but EBITDA contribution is immaterial
Arinna Lifesciences Acquisition Integration
Expected benefit
Entry into Indian formulations with CNS focus, 60 brands, ~160 sales reps, and 4,000+ active prescribers
Risks
Short-term margin dilution; currently investing behind growth before profitability
Timeline
Aiming to beat Indian Pharma Market (IPM) growth before focusing on margin improvement
Investment
INR 175.9 cr cash consideration
SourceNitin Jajodia: 'Our focus is investing behind the growth and getting the growth back on track... then we will start focusing on profitability' (Transcript, original pages 3, 12; Presentation, original pages 6, 8, 34)
capacity expansion · Acquired in FY26 from Alkem; pre-revenue with two procedural US FDA observations from July 2026 inspection (EIR awaited)
Manufacturing site for steroids, hormones, high-potency oral solids, and topicals (built-up area of ~16,000 m2)
Risks
Pre-operative costs flowing through P&L without offsetting revenue
Timeline
Revenue generation expected from FY28 onwards
Investment
INR 158.1 cr capital employed
SourceParag Sancheti: 'For Indore, we have already said that it will be FY 2028 onwards for that' (Transcript, original page 11; Presentation, original pages 8, 34)
Things to check
Multiple US FDA Form 483 observations across active manufacturing facilities awaiting regulatory clearanceSourceFive observations issued at Ambernath in Oct-26, one observation at Satara in Oct-26, and two observations at Pithampur in Jul-26; all three facilities are awaiting EIR closure (Presentation, original page 12)
Substantial capital locked up in non-earning assetsSourceINR 396.2 cr (25.6% of sources of funds / total capital employed) is tied up in pre-revenue manufacturing assets and Arinna, with all running costs absorbed in current P&L (Presentation, original page 8; Transcript, original page 4)
How the call went
The call provided detailed disclosures regarding R&D productivity and balance sheet allocation, but management was tight-lipped on commissioning timelines for two manufacturing sites and profitability expectations for Arinna.
Specific or vague
Management provided precise operational metrics on R&D productivity cycles, R&D spend to date, and balance sheet capital split
Candour
Management was forthright about pre-revenue drag on ROACE and procedural FDA observations, but deflected on specific timelines and future margin outlook for acquisitions
The hard questions
Analysts questioned historical R&D failure rates, audited base revenue reconciliations, commercial timelines for pre-revenue sites, and Arinna margin potential
What analysts pressed on
Return on capital profile and P&L cost impact from pre-revenue sites (Pithampur, CSN, New Jersey)
Timing of revenue ramp-up from newly acquired plants
Margin trajectory and integration progress of Arinna Lifesciences
Efficiency of R&D capital allocation and proportion of aborted R&D pipeline projects
Answers that sidestepped
Parag Sancheti refused to provide commercialization timelines for CSN and New Jersey facilities ('Right now, we will refrain from giving an exact date for that')
Management declined to provide medium-term margin guidance for Arinna ('instead of guiding, we believe in doing and not talking... we are sometime away from that phase')
Numbers against the story
Management emphasized that R&D productivity is accelerating to 5.8x-5.9x; however, their presentation and remarks acknowledge that the FY27 reference cycle came off the lowest absolute R&D spend base (INR 218.7 cr) of the last three cycles, making the multiple optically elevated, and the FY27 revenue base used for the calculation is an arithmetic annualization of H1 (ex-Arinna). Additionally, headline revenue growth of 39.9% includes Arinna's INR 19.4 cr consolidation, which contributed zero to operating EBITDA.
Figures: the company’s results filing with NSE, linked under the table.
Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.